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Implications for Rehabilitation 
 
• Powered wheelchairs have therapeutic benefits in managing muscular 
dystrophy pain and weakness 
• The use of specialised seating needs careful consideration in supporting 
progressive muscle weakness and the management of scoliosis. 












Clinical features of children and adults with a muscular dystrophy using 
powered indoor/outdoor wheelchairs: disease features, comorbidities and 
complications of disability. 
Abstract 
Purpose: To describe the clinical features of electric powered indoor/outdoor 
wheelchair users with a muscular dystrophy, likely to influence optimal 
prescription; reflecting features of muscular dystrophies, conditions secondary 
to disability and comorbidities impacting on equipment provision. Methods: 
cross-sectional retrospective case note review of recipients of electric powered 
indoor/outdoor wheelchairs provided by a specialist regional wheelchair service. 
Data on demography, diagnostic/clinical and wheelchair prescription were 
systematically extracted. Results: Fifty-one men and 14 women, mean age 23.7 
(range 10-67, sd 12.95) years, were studied. Forty had Duchenne muscular 
dystrophy, 22 had other forms of muscular dystrophy and three were 
unclassified. Twenty-seven were aged under 19. Notable clinical features 
included problematic pain (10), cardiomyopathy (5) and ventilatory failure (4). 
Features related to disability were (kypho)scoliosis (20) and oedema/cellulitis (3) 
whilst comorbidities included back pain (5). Comparison of younger with older 
users revealed younger users had more features of muscular dystrophy affecting 
electric powered chair provision (56%) whilst older users had more comorbidity 
(37%). Tilt-in-space was prescribed for 81% of users, specialised seating for 
55% and complex controls for 16%. Conclusions: Muscular dystrophy users 
were prescribed electric powered indoor/outdoor chairs with many additional 
features reflecting the consequences of profound muscle weakness. In addition to 
facilitating independence and participation, electric powered indoor/outdoor 
chairs  have major therapeutic benefits. 
 
Introduction  
Muscular dystrophy, including myotonic dystrophy, is a term covering a set of 
chronic, hereditary and progressive diseases involving degeneration of muscle 
cells and leading to successive wasting of the muscles including the respiratory 
muscles.[1] Limb girdle muscular dystrophy is now recognised as a 
heterogeneous group of myopathies that vary in severity and may affect persons 
of all ages from childhood through adulthood.[2] Life expectancy has improved 
markedly in recent years and Duchenne muscular dystrophy is now considered a 
disease of adulthood.[3] 
The muscular dystrophies are rare diseases, with a ‘combined prevalence 
between 19.8 and 25.1 per 100,000 person years’.[4] The prevalence of the 
commonest types are fascioscapulohumeral dystrophy (3.2-4.6 per 100,000), 
myotonic dystrophy (0.5-18.1 per 100,000) and Duchenne muscular dystrophy 
(1.7–4.2 per 100,000).[4] All those with Duchenne muscular dystrophy will 
become wheelchair reliant in childhood, usually by the age of 12 years unless 
treated.[5] The United Kingdom (UK) Registry of fascioscapulohumeral 
dystrophy has reported that about 40% of those registered used wheelchairs at 
least part-time.[6] The mean age of achieving wheelchair reliance for those with 
Becker muscular dystrophy was 50 years.[7] Use of powered wheelchairs or 
powered mobility has been reported from 7% for those with Duchenne muscular 
dystrophy [8] to 31% of individuals with neuromuscular disease.[9]The 
transition of both health and social support as children transfer to adult services 
at the age of 19 years is recognised as problematic [10-11] with inadequate adult 
health provision for those ageing with childhood deteriorating conditions.[12] 
Powered mobility is now becoming more important as its value is increasingly 
accepted not only as a means of improving mobility and independence [13-14], 
increasing quality of life for those with muscular dystrophies,[15] potential 
savings in social costs [16] but also because of its direct therapeutic effects.[17-
18] Guidelines for those with limb girdle muscular dystrophies recommend the 
‘prescription of assistive devices that are adapted specifically for the patient’s 
deficiencies’ [2] and guidelines for those with Duchenne muscular dystrophy 
recommend assistive technology and manual/powered wheelchairs as part of 
rehabilitation management.[14] The emphasis has therefore shifted from 
powered wheelchairs being aids for mobility to being facilitators of participation 
and occupation. Additionally, it is acknowledged that powered wheelchairs are 
fundamental in optimising medical management for those with long-term 
disabling conditions.[18]  
While powered wheelchairs are used to increase function and mobility their 
provision is equally important for minimising discomfort and postural 
abnormalities.[19] It is acknowledged that, as people with Duchenne muscular 
dystrophy grow older, they acquire a wide range of clinical complications that 
need management,[20] often through specialised seating (adaptive seating) on the 
powered wheelchair base. The major clinical issues relate to orthopaedic 
complications including fractures, (kypho)scoliosis, cardiopulmonary 
involvement [20] and pain.[9,21-22] 
Postural problems such as a scoliosis are known to develop when individuals are 
still ambulant.[23] Specialised seating can provide appropriate postural support 
but this may conflict with the desire of the chair user (hereafter described as the 
‘user’) to keep mobile within the chair [21] which may challenge a wheelchair 
provider. This challenge is compounded during the years of growth [21] and the 
curve may progress even after cessation of growth,[24] associated with the 
increasing muscular weakness. Regular monitoring and careful management of 
the spinal complications of muscular dystrophy is recommended to maintain 
optimal posture and cardiopulmonary function.[2] 
The progressive muscular weakness characteristic of the muscular dystrophies 
determines the development of a range of clinical manifestations which depend 
on the disease trajectories of the different types of muscular dystrophy. Many of 
the common features of muscular dystrophy have been documented.[2,14,25] 
Individuals may also develop health conditions associated with long-term 
disability. These features of disability have been reported in other powered 
wheelchair users.[17,26] In addition, individuals may be diagnosed with other 
conditions unrelated to the muscular dystrophy, comorbidities, although they 
may reflect age-related health issues.[27] Collectively, these have been referred 
to as ‘Associated Clinical Features’ (ACFs) [17,26] as it is acknowledged that 
some ambiguity exists due to lack of research into the development of conditions 
across the lifespan of disease. 
The aims of this study are to describe the clinical features of electric powered 
indoor/outdoor chair users with muscular dystrophy and to explore the 
complexities of comorbidities, features of muscular dystrophy and conditions 
secondary to disability that impact on powered wheelchair provision and clinical 
management. A further aim is to compare the clinical features and electric 
powered indoor/outdoor chair provision of those under the age of 19 years with 
those aged 19 or over. 
Methods 
This is a cross-sectional study of a clinic population and was approved by the 
National Research Ethics Service as a service evaluation. 
The participants 
The potential participants for this study were wheelchair users with a muscular 
dystrophy referred from locality based wheelchair services to a specialist 
wheelchair service serving a mixed population from inner city, suburban and 
rural areas of approximately 3.1 million. Following assessment of suitability for 
an electric powered indoor/outdoor chair, those who fulfilled eligibility criteria 
[28] were included. Details of the specialist wheelchair service and the full 
assessment for electric powered indoor/outdoor chair eligibility have been 
described elsewhere.[26] In essence, those unable to self-propel and who were 
able to take advantage of using a powered chair indoors and outdoors safely 
were included.  The study participants had been provided with an electric 
powered indoor/outdoor chair and were currently using it.  
Procedures 
Data consisting of demographic data, clinical issues and wheelchair factors were 
entered into electronic records and reviewed between June 2007 and September 
2008 by a consultant physician in rehabilitation medicine. They were 
systematically extracted and entered into a computer database. Average time 
from the date of initial assessment for an electric powered indoor/outdoor chair 
in clinic to the case note review was 5.28 (range 0-10.7, sd 3.23) years. Further 
data were entered from clinical notes (charts) and anonymised.  
Demographic profiles consisted of age at initial assessment and gender. Where 
the database held no precise diagnostic information relating to the type of 
muscular dystrophy, it was classified as ‘unknown’. 
Clinical profiles perceived to be relevant to the electric powered indoor/outdoor 
chair prescription included comorbidities, complications relating to muscular 
dystrophy or disability. Due to the ambiguity in which some clinical features may 
reflect either the muscular dystrophy itself, co-morbidity or a complication of 
disability, they were grouped as ACFs when referred to collectively.[17] Users 
requiring further clinical management were referred to their family doctor 
(primary care doctor). 
Pain is a major problem for many with a muscular dystrophy.[14] Users with 
pain requiring further investigation/management, or influencing the electric 
powered indoor/outdoor chair prescription were recorded as ‘problematic 
pain’.[17,26] 
Features noted by others as being disability related were also included. They 
were spinal deformities,[29-30] osteoporosis, [5,31] pelvic obliquity,[29] 
contractures, [2,5,32] thrombo-embolism,[33] dependent oedema [18,34] and 
pressure sores.[21] Conditions classified as comorbidities were those considered 
unrelated to muscular dystrophy.  
Wheelchair factors included information about specialised seating, defined as 
that which is ‘required by those who need a wheelchair for their mobility but 
due to postural instability or deformity need extra support in order to 
function’[35,p.7]. Other data included tilt-in-space, cushions, complex controls, 
chair mounted ventilation and use of the National Health Service Voucher 
Scheme.[36] 
Methods of analysis 
This was a secondary data analysis of a sub-group of electric powered 
indoor/outdoor chair users from a cohort reported elsewhere.[37] Descriptive 
statistics were used to analyse demographic, clinical and wheelchair data. 
 
Results 
Sixty five users mean age 23.7 (range 10-67, sd 12.95) years (table1), comprised 
51men mean age 22.6 (range 10-67, sd 12.9) years and 14 women mean age 27.7 
(range 10-49, sd 12.9) years. The dominant group of users had Duchenne 
muscular dystrophy and this group were the youngest with a mean age of 18 
years (table 1).Twenty seven users were aged under 19 years, the youngest aged 
10, whilst 38 users were aged 19 and older, the oldest aged 67 (table 2). 
Suggest insert table 1 and table 2 about here. 
Associated clinical features 
Twenty five users had no ACFs. Nineteen had one ACF, 14 had two ACFs whilst 
seven had more than two ACFs. Of the 40 users with Duchenne muscular 
dystrophy, 27 had at least one ACF. 
We noted 10 comorbidities reported in 18 users, the most common being back 
pain in five users. Hypertension and ischaemic heart disease were noted in users 
aged 54, 57 and 60. Two users, both with congenital muscular dystrophy 
experienced cerebrovascular events; one 33 year old had a stroke and the other 
aged 13 had an intracranial bleed. There were nine features of muscular 
dystrophy reported by 26 users with problematic pain being the most frequent 
reported by 10 users.  Scoliosis was the most frequently noted of the six 
complications of disability (n=20; 10 younger and 10 older users) (table 3). No 
reports were noted for thromboembolism.  
Comparison of those under 19 years with older users revealed that the younger 
group had more features of muscular dystrophy affecting electric powered 
indoor/outdoor chair provision (56%) whilst the older users had more 
comorbidity (37%). The complications of disability were proportionately similar 
for younger (44%) and older (42%) users (table 2). Four users had ventilatory 
failure, mean age 22 years, three with Duchenne muscular dystrophy and one 
with congenital muscular dystrophy and required oxygen cylinders to be 
accommodated by the electric powered indoor/outdoor chair. Two of these users 
had tilt-in-space and three had specialised seating. All four were provided with 
tray-mounted complex controls. 
Thirty-seven users were noted to have clinical issues that needed further 
attention from their family doctor (primary care team).  The majority of these 
referrals related to medical issues, about half of which concerned the need for 
pain management.  
Suggest insert table 3 about here. 
 
Wheelchair features 
Tilt-in-space was provided to 48 (81% of those with known data) users (table 1). 
Eighty five percent of younger users were provided with tilt-in-space, compared 
with 66% of older users (table 2). Just over half of the cohort was provided with 
specialised seating (table1) with 74% of younger users compared with 42% of 
older users having this feature (table 2). Sixty five percent of users with 
Duchenne muscular dystrophy were prescribed specialised seating compared to 
40% of other muscular dystrophy users. Thirty one users were provided with 
both specialised seating and tilt-in-space although two users with specialised 
seating had unknown tilt-in-space provision. 
Contoured systems were provided to 12 users: carved foam (4), Scott seating 
systems (4), matrix (3) and moulded seat insert. The majority of the remainder 
had pressure relieving cushions, mainly Jay 2 cushion (14), Qbitus (10), Vicaire 
(4) and RoHo (3) and Other (n=7). Fifteen were provided with a standard 
wheelchair cushion. 
Complex controls were provided to 17 users of which 14 were tray mounted, 
seven were non-standard and six had interfacing issues with other assistive 
technology devices. A further three users were referred for environmental 
control units. 
The voucher scheme was used by three users/parents. One 11y old boy with limb 
girdle muscular dystrophy provided with a ‘riser’ function in partnership with 
the charity ‘WhizzKidz’; another 12y old boy with Duchenne muscular 
dystrophy provided with a ‘lying-to-stand function’ in partnership with 
WhizzKidz; and a 12y old boy with Duchenne muscular dystrophy whose 
parents were very unhappy with the service provided and preferred the 
individual responsibility for maintenance of the electric powered indoor/outdoor 
chair. 
Discussion 
Extensive follow-ups of electric powered indoor/outdoor chair users with a 
muscular dystrophy are rare. This report of a UK group spans an average of 5.3 
years of electric powered indoor/outdoor chair use by individuals with muscular 
dystrophy. Our group of users are atypical when compared to other muscular 
dystrophy populations. Firstly, they are all severely disabled, unable to walk, and 
due to the strict eligibility criteria for electric powered indoor/outdoor chair 
provision,[28] those with poorly controlled epilepsy, learning disability and 
cognitive dysfunction are under-represented. Some of these users have been 
reported previously at a two-year follow-up.[21]  
These muscular dystrophy electric powered indoor/outdoor chair users were on 
average older than most other muscular dystrophy populations as age was not a 
criterion for selection. However, our youngest user was aged 10 years as might 
be expected from the likely age of loss of walking in Duchenne muscular 
dystrophy [38-39] and is comparable to those reported by Engle et al in a mixed 
population of users with both muscular dystrophy and myotonic dystrophy.[9] 
Studies that include both children and adults of all ages are rare, although 
Pangalila has reported those with Duchenne muscular dystrophy aged up to 
44.[40] Those with Becker muscular dystrophy and fascioscapulohumeral 
dystrophy become wheelchair dependent when older as reflected in our data and 
that of Wood et al.[6] 
Clinical features of Muscular Dystrophies 
The progressive muscular weakness characteristic of muscular dystrophies 
results in the decline of functional ambulation at which point powered mobility is 
advocated.[14] Our study indicates that the loss of ambulation can occur across 
the age range depending on the type of muscular dystrophy. The reasons for 
provision of electric powered indoor/outdoor chairs not only relate to mobility 
factors but also to the expectations of individual’s community participation at 
different stages of their life.[37] The needs of younger users, in this study mainly 
those with Duchenne muscular dystrophy, include facilitating engagement in 
school and play while at the same time accommodating growth and anticipated 
disease progression. Older users, in this study mainly those with other forms of 
muscular dystrophy, have needs relating to families, work and active retirement.  
The independence provided by an electric powered indoor/outdoor chair 
facilitates psychological and social development for younger users’ [41] and 
community living for older ones.[42]  
In order to achieve this, electric powered indoor/outdoor chair prescription with 
appropriate additional features such as specialised seating, should be used to 
reduce the impact of symptoms and maintain or improve residual function. The 
findings of this study bring together the main technical considerations of electric 
powered indoor/outdoor chair provision with clinical information relating to 
muscular dystrophies and severe disability.  
Pain is a recognised feature of Duchenne muscular dystrophy with higher levels 
reported for those still mobile as compared to wheelchair users.[43] It is a 
significant problem for young people with Duchenne muscular dystrophy 
affecting most parts of the body and interfering with several life domains.[9] 
Engle’s patients’ reported the ‘pain as negatively affecting many aspects of youth 
and adolescent life’ [9] and also that some had severe pain which is consistent 
with our findings of problematic pain. Pain was also reported in adult patients 
with Duchenne muscular dystrophy but appeared not to interfere greatly with 
activities.[40] Back pain, together with leg and neck pain, are reported as 
common sites of pain in neuromuscular disorders.[9] This is consistent with our 
findings and indicates the need for adjustment and review of seating [21] which 
in this study showed that specialised seating was required by the majority of 
users, especially those under 19 years of age.  
The incidence of neck pain was extremely low with only one user reported with 
this problem. The likely reason was that neck restraints were provided as 
standard to all our users. This is particularly important for those with 
progressive weakness and, in tandem with using tilt-in-space, provides 
appropriate support for the head and neck. This is an important contribution to 
their rehabilitation through facilitating head control. Provision of tilt-in-space 
also makes an important contribution to pain management as it allows the user 
to change position as frequently as they wish in order to minimise the pain and 
discomfort associated with prolonged sitting. Our results show a high proportion 
of all muscular dystrophy electric powered indoor/outdoor chair users being 
provided with tilt-in-space.  
 
Our four users with ventilatory support all had complex control systems as has 
been reported previously.[44] Cardiomyopathy and chronic respiratory 
insufficiency are universal in the later stages of Duchenne muscular 
dystrophy.[5] It is debateable whether respiratory insufficiency is a consequence 
of muscular dystrophy progressive weakness or due to chest wall and spinal 
deformities reducing respiratory capacity.[45] In this cohort, specialised seating 
systems were used therapeutically to facilitate reduction of spinal deformity 
during growth, although after growth seating accommodated any spinal 
deformity.  A balance must be sought between stability and flexibility to allow 
those who use a ‘row-a-boat’ breathing to have sufficient movement in their 
chairs.[46] 
Comorbidity 
Reports of comorbidities in the muscular dystrophies are rare. However, the 
‘prevention and management of comorbidities’ is important.[2,p.1461] In 
common with this study, asthma has been reported as a comorbidity in a sample 
of youths [9] as has an increased risk of bone fractures in Duchenne muscular 
dystrophy.[5,47] The one user we noted with multiple fractures of both distal 
femurs and proximal tibiae had tipped out of his wheelchair, a known risk for 
electric powered indoor/outdoor chair users.[28] Also consistent with previous 
studies,[48] we had two users with epilepsy – one noted to be temporal lobe, the 
other unspecified. This may be unrepresentative as some potential users with 
epilepsy will not fulfil the eligibility criteria [28] due to inadequate epilepsy 
control. We have noted epilepsy as a comorbidity although recent research may 
indicate it is part of the spectrum of Duchenne muscular dystrophy.[49] 
Comorbidities such as hypertension and ischaemic heart disease may be 
considered due to the ageing process, possibly related to the sedentary lifestyle 
consequent to wheelchair reliance. The cerebrovascular events noted for two 
electric powered indoor/outdoor chair users with congenital muscular dystrophy 
appear not to have been reported previously, but it is speculated that they may 
be due to cortical abnormalities noted in this condition.[50] 
Disability features 
One of the greatest challenges for wheelchair prescribers and those with 
muscular dystrophies is the development of a scoliosis. [24,51-52] It has been 
reported that the magnitude of the curve was predicted by the length of time 
using a wheelchair. [53] We found 20 (31%) users with a scoliosis that required 
addressing through the electric powered indoor/outdoor chair provision. Seeking 
an appropriate balance between stabilising the spine and retaining upper limb 
and trunk flexibility in the system is complex and the views of the user and their 
family’s priorities may produce tensions that need resolution by the seating 
team.[26] For example, many of the users also used their manual backup chair to 
extend their social life beyond the reach of their powered chair.[41] This creates 
extra physical strain for the parents of these young users when they have to 
transfer the seating system from their electric powered indoor/outdoor chair to 
their manual chair. Postural issues are critical in this group and are greatly 
complicated by the influence of growth often needing adjustments to the electric 
powered indoor/outdoor chair within one year of prescription.[21] 
Dependent oedema is a well established complication of prolonged sitting [18] 
and has been noted previously in other electric powered indoor/outdoor chair 
user groups [17,26] but may also be due to electrolyte imbalance in Duchenne 
muscular dystrophy.[54] 
 
Pressure problems are well recognised for wheelchair dependent wheelchair (not 
necessarily powered wheelchair) users with Duchenne muscular dystrophy.[55] 
Pressure problems appear to be better controlled now than when reported from 
this service previously.[21] However, the presence of two pressure sores suggests 
that further measures need to be taken to ensure adequate protection against 
pressure. 
Wheelchair issues 
In contrast to other electric powered indoor/outdoor chair user groups, [17,26] 
these users with muscular dystrophies had a higher frequency of provision of SS 
and TIS which was particularly found for those under 19 years of age with 
almost half the cohort being provided with both specialised seating and tilt-in-
space. We also found that the users with Duchenne muscular dystrophy were 
most frequently provided with specialised seating. This indicates both the 
severity of the disability, the likelihood of its progression and the complexity of 
meeting individuals’ needs through the rehabilitation process.  
The value of tilt-in-space has been noted previously for those with muscular 
dystrophy. [21,34] It has been recommended as good practice in the management 
of muscular dystrophies for reducing the impact of gravity on a scoliosis, 
pressure redistribution, increasing comfort and pain relief, reducing fatigue, 
increasing independence for the chair user to change position and assisting 
carers in moving/handling in the management of personal care.[34] For this 
cohort of electric powered indoor/outdoor chair users with muscular dystrophy, 
these issues were considered across the age range to include chair use at home, in 
school, college/university, the workplace and the outdoor environment. 
Specialised seating is primarily provided to improve sitting posture, but is also 
reported to facilitate small improvement in upper limb function,[51] both of 
which are important for facilitating function and participation. For users who 
are children or adolescents, specialised seating may require change or adaptation 
to accommodate growth.[21] Those needing the most support in this study (12 
users) were provided with individually fitted specialised seating. These are likely 
to be the most severely impaired (e.g. through a scoliosis) and vulnerable 
individuals with muscular dystrophies maintained in the community.  
Specialised seating was provided for a number of other reasons, the most 
important being pressure redistribution, prolongation of sitting time, preventing 
contractures and providing the additional support needed to negotiate ramps 
and slopes.[34] 
Trays can be used to provide additional support for the upper limbs when arm 
rests prove insufficient.[34] This is particularly important where muscle 
fatigue/weakness limits the residual functions of the hands to control the electric 
powered indoor/outdoor chair. Provision of a tray-mounted control box 
alleviated this issue for 14 of our users, six of whom utilised the tray for 
interfacing with other equipment. Where the control box can be positioned 
centrally, a more symmetrical posture is achieved. Complex controls, when 
needed, included light touch systems appropriate for those with extreme muscle 
weakness as reported previously.[44] 
For the four users who needed ventilatory support, the electric powered 
indoor/outdoor chair prescription would have to take into account the weight of 
the oxygen cylinders which are usually mounted on the back of the chair. The 
engineers would allow for the use of tilt in making their prescription. It is not 
surprising that those whose cardio-respiratory weakness required ventilatory 
support also had such severe peripheral weakness that tray-mounted complex 
controls were needed.  
Health-related quality of life is severely affected by Duchenne muscular 
dystrophy [56] and the consequent socioeconomic costs of direct, indirect and 
informal care costs are substantial.[56] The complexity of meeting the 
requirements of those with muscular dystrophy who need powered mobility is 
reflected in the electric powered indoor/outdoor chair prescription. Thus the 
proportion of those with muscular dystrophy being provided with tilt-in-space, 
tilt-in-space and specialised seating, and complex controls is greater than for 
those with multiple sclerosis,[17] rare diseases,[26] spinal cord injuries [57] and 
cerebral palsy [58]. The need for these extra features increases the capital cost of 
providing the electric powered indoor/outdoor chair, and also the need for extra 
time from the highly skilled team of rehabilitation professionals giving the 
assessment, provision and maintenance of the chair. 
Strengths and limitations 
This is one of the few studies with a five year period of follow-up that addresses 
the needs of both children and adults severely affected with a muscular 
dystrophy who use powered wheelchairs. A strength of this study was that all 
users were seen by the same multiprofessional team who were very experienced 
in the provision of powered wheelchairs and therefore the clinical decisions made 
were consistent and in accordance to service protocols.  
Our electric powered indoor/outdoor chair users with muscular dystrophy were 
predominately those with Duchenne muscular dystrophy. Therefore, it is 
difficult to comment further on the more specific needs of those with other types 
of muscular dystrophy.  In addition, we lacked precise diagnostic data regarding 
the type of muscular dystrophy in three users. We acknowledge missing data on 
the presence or absence of tilt-in-space in six users. 
The service records did not gather data on the use of elevating leg rests or recline 
features of the electric powered indoor/outdoor chair provided and this is 
regrettable as these features have major therapeutic benefits, but at additional 
costs.  
The nature of the provision of electric powered indoor/outdoor chairs in the UK 
at the time of the study meant that electric powered indoor/outdoor chair s were 
provided to very few children below secondary school age (10-11 years) and thus 
the undoubted benefits of powered mobility for younger children were not 
assessed.  
We recognise that the presence of ACFs is likely to be under-reported as data 
was obtained from referral letters and patient histories. However, such data is 
more likely to be objective than purely patient self-report surveys. Further 
prospective studies are recommended.  
This study did not include those who used scooters or had purchased their 
powered wheelchairs privately or with charitable funding (mostly available for 
children only).  
Conclusions 
In addition to facilitating independence and participation for those with a 
muscular dystrophy, powered wheelchairs have major therapeutic benefits, 
particularly in the management of wheelchair users’ pain and weakness in 
addition to the more recognised benefits of pressure relief.  
A (kypho)scoliosis, problematic pain and ventilatory failure were the clinical 
features most likely to influence the electric powered indoor/outdoor chair 
prescription. Frequent use of specialised seating and tilt-in-space were utilised to 
facilitate management of these clinical complications, whilst accommodation of 
the ventilatory equipment required adjustments to the electric powered 
indoor/outdoor chair.  
The use of powered tilt-in-space, specialised seating and complex controls was 
greater than for any other group of electric powered indoor/outdoor chair users 
studied to date and this reflects the complexity of meeting the needs of those with 
profound peripheral muscle weakness. This utilisation was greater for the 
children than for those aged 19 years or older and is likely to reflect not only 
growth issues but also the rapid deterioration of those with Duchenne muscular 
dystrophy and some other congenital forms of muscular dystrophy. The need for 
a high use of these electric powered indoor/outdoor chair features will have cost 
implications for neuromuscular service providers.  
Disclosure Statement: The authors report no conflicts of interest. 
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* Only one user 

























Becker’s 2 (2) 42  
(24-60) 
0 1 0 0 0 
Congenital 11 (2) 23  
(11-34) 
7 9 3 5 1 
Duchenne 40 (40) 18  
(10-34) 
26 31 13 14 8 
Dystrophia 
Myotonica 




2 (2) 45 
(33-57) 
 
0 0 0 0 0 
Limb-girdle 6 (2) 36 
(11-49) 
2 4 1 0 1 
Unknown 3 (2) 37 
(10-67) 
1 2 0 1 0 
Total 65 (51) 23.7 
(10-67) 
36 48 17 20 10 
Table 2. Clinical features and wheelchair provision for 27 users with a muscular 
dystrophy aged under 19 and 38 users aged 19 or over. 
Age group Under 
19 
19 or more Total 




(10 – 18) 
30.7 
(19 – 67) 
23.7 
(10 – 67) 
Special Seating n (%) 20 (74) 16 (42) 36 (55) 
Tilt-in-Space n (%) * 23 (85) 25 (66) 48 (74) 
Complex controls n (%) 6 (22) 11 (29) 17 (26) 
Features of muscular 
dystrophy n (%) 
15 (56) 11 (29) 26 (40) 
Comorbidity 4 (15) 14 (37) 18 (28) 
Complications of disability 12 (44) 16 (42) 28 (43) 
 









Table 3.  Frequency of comorbidity, features of muscular dystrophy and 
complications of disability in 65 users with a muscular dystrophy. 
Comorbidity Feature of MD Complication of disability 
Back pain (5) Recurrent chest infections 
(2) 
Scoliosis (20) 
Hypertension (2) Weight loss  Dependent oedema/cellulitis 
(3) 
Asthma (2) Cardiomyopathy (5) Pressure sores (2) 
Cerebrovascular events (2) Problematic pain (10) Hip problems 
Epilepsy (2) Ventilatory failure (4) Pelvic obliquity  
Arthrogryposis Learning difficulties Contractures 
Piles Swallowing difficulties  
Fractures Ureteric reflux with 
recurrent urinary tract 
infections 
 
Neck pain Sleep disturbance  
Ischaemic heart disease   
Total = 18 Total = 26 Total = 28 
 
 
 
 
 
 
